GLP-1 Research

New research reveals tirzepatide drives powerful fat loss and visceral fat reduction, but also significant lean mass loss…

Up to 45% of weight lost on semaglutide can come from muscle — here is what the latest…

A comprehensive breakdown of what the latest GLP-1 research — including the 2025 STRIDE trial — reveals about…

New DXA and MRI data from major tirzepatide trials reveal how the drug reshapes body composition — and…

GLP-1 medications can drive significant muscle loss in the first year — here's what the research shows and…

Semaglutide is sold under three brand names — Ozempic, Wegovy, and Rybelsus — each approved for different clinical…

Emerging research suggests GLP-1 receptor agonists not only avoid increasing depression risk but may offer direct neuropsychiatric benefits…

Stopping Ozempic triggers powerful hormonal rebound mechanisms that drive weight regain — here's what the research shows and…

Tirzepatide has produced up to 20% weight loss and a 93% reduction in diabetes progression in major clinical…

Tirzepatide has now outperformed semaglutide head-to-head and cut diabetes progression risk by 93% in three-year trials — here's…